LEGN (Legend Biotech) FCF Margin %: -30.35% (As of Mar. 2026)


LEGN Legend Biotech Corp LEGN
73 GF Score
Price $28.44
GF Value $98.47
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Legend Biotech FCF Margin %?

Legend Biotech LEGN -3.22% 73 FCF Margin % is -30.35% as of Mar. 2026. GuruFocus rates LEGN with a GF Score™ of 73/100 and a GF Value™ of $98.47 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Legend Biotech ranks better than 68.12% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Legend Biotech's Free Cash Flow for the three months ended in Mar. 2026 was $-93 Mil. Legend Biotech's Revenue for the three months ended in Mar. 2026 was $305 Mil. Therefore, Legend Biotech's FCF Margin % for the quarter that ended in Mar. 2026 was -30.35%.

As of today, Legend Biotech's current FCF Yield % is -2.11%.

The historical rank and industry rank for Legend Biotech's FCF Margin % or its related term are showing as below:

LEGN' s FCF Margin % Range Over the Past 10 Years
Min: -354.33   Med: -168.49   Max: 583.44
Current: -10.17

During the past 8 years, the highest FCF Margin % of Legend Biotech was 583.44%. The lowest was -354.33%. And the median was -168.49%.

LEGN's FCF Margin % is ranked better than
68.12% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs LEGN: -10.17

Legend Biotech FCF Margin % Related Terms

Legend Biotech FCF Margin % Historical Data

* Premium members only.

The historical data trend for Legend Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Legend Biotech FCF Margin % Chart

Legend Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -354.33 -191.07 -145.91 -25.20 -12.52

Legend Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.15 -8.79 8.74 -8.02 -30.35

LEGN vs DNTH, XENE, CAI: FCF Margin % Comparison

For the Biotechnology subindustry, Legend Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Legend Biotech FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Legend Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Legend Biotech's FCF Margin % falls into.


LEGN
73GF Score
Legend Biotech Corp LEGN
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Legend Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Legend Biotech's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-128.8/1028.9
=-12.52 %

Legend Biotech's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-92.6/305.1
=-30.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -30.35% mean?
Legend Biotech (LEGN) has a FCF Margin % of -30.35% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Legend Biotech and its competitors. According to the industry distribution chart, Legend Biotech ranks #306 out of 960 companies in the Biotechnology industry, placing it in the top 31.9%.
Is Legend Biotech's FCF Margin % too high?
Legend Biotech's current FCF Margin % is -30.35%. Based on the distribution chart, Legend Biotech ranks #306 out of 960 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Legend Biotech has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's FCF Margin % compare to DNTH and XENE?
According to the Biotechnology industry distribution chart, Legend Biotech ranks #306 out of 960 companies for FCF Margin %. This puts Legend Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Legend Biotech and its competitors. Legend Biotech's current FCF Margin % is -30.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $98.47, compared to a current price of $28.44 — trading 71.1% below its estimated fair value. The current FCF Margin % is -30.35%. Legend Biotech's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Legend Biotech (LEGN), the current FCF Margin % is -30.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Legend Biotech (LEGN) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of $28.44 is trading 71.1% below its estimated GF Value™ of $98.47. GuruFocus considers Legend Biotech to be Possible Value Trap.

Key valuation signals for LEGN:

  • FCF Margin %: -30.35%
  • GF Value™: $98.47 vs. price of $28.44 (71.1% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Legend Biotech Business Description

Other Exchanges 9LB:Germany
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
73GF Score

Get the complete analysis for LEGN

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.44
Price
$98.47
GF Value